Skeptical Perspectives on Aging Research: Evaluating Evidence Quality Across Longevity Interventions

The article examines cautious academic and pharmaceutical viewpoints on geroscience research, noting that despite billions in funding, questions remain about whether aging can be practically slowed or reversed in humans as demonstrated in laboratory settings. The author argues that different therapeutic approaches within the longevity field should not be treated as equivalent, contrasting interventions like NAD+ upregulation with senolytic therapies, which have substantially different levels of supporting evidence. The piece emphasizes that while many rejuvenation approaches show promise, rigorous evaluation of their distinct evidence bases is essential before drawing conclusions about their clinical utility.

The longevity research field currently faces a credibility gap between promising laboratory findings and proven human benefits. While established drugs like metformin and rapamycin show extensive preclinical support, their ability to meaningfully extend human healthspan remains unconfirmed through clinical trials. This gap reflects a fundamental challenge in translating aging biology: laboratory demonstrations don't automatically predict real-world effectiveness in human populations.

The article highlights a critical distinction often overlooked in broader discussions of anti-aging therapies. Senolytics—drugs designed to eliminate senescent cells—rest on more robust animal evidence and larger observed effects than NAD+ boosting approaches, which have generated inconsistent results across multiple failed human trials. Lumping these disparate interventions together obscures important differences in scientific maturity and evidence quality.